Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment – the company’s Phase 2 trial in patients with acute-on-chronic liver failure (ACLF), Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with severe renal impairment – after the market close on Thursday, January 8, 2015. Conatus will host a conference call and webcast with an associated presentation at 4:30 p.m. Eastern Time on Thursday, January 8, 2015, to discuss the trial results… Read more
Shares of Conatus Pharmaceuticals closed last Friday at $8.09 . They have a 1-year high of $15.67 and a 1-year low of $5.06. The stock’s 50-day moving average is $7.53 and it’s 200-day moving average is $7.28.
On the ratings front, Conatus Pharmaceuticals has been the subject of a number of recent research reports. In a report published on November 26, analyst Ed Arce from Roth Capital reiterated a Buy rating on CNAT, with a price target of $19, which implies an upside of 134.9% from current levels.
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease.